Recent studies demonstrated that intravaginal rings (IVRs) containing 100 mg of the nonnucleoside
reverse transcriptase inhibitor (NNRTI)
MIV-150 significantly protect macaques against a chimeric simian-human immunodeficiency virus that expresses the HIV-1 HxB2
reverse transcriptase (SHIV-RT) when present before and after vaginal challenge. The objectives of this study were to (i) evaluate the pharmacodynamics (PD) of
MIV-150 in vaginal fluids (VF) and in ectocervical and vaginal tissues following 100-mg
MIV-150 IVR exposure and to (ii) gain more insight whether pharmacokinetics (PK) of
MIV-150 can predict PD.
MIV-150 in VF collected at 1 day and 14 days post-MIV-150 IVR insertion inhibited ex vivo SHIV-RT
infection in vaginal biopsy specimens from untreated animals (not carrying IVRs) in a dose-dependent manner. Previous PK studies demonstrated a significant increase of ectocervical and vaginal tissue
MIV-150 concentrations 14 days versus 1 day post-IVR insertion, with the highest increase in vaginal tissue. Therefore, we tested PD of
MIV-150 in tissues 14 days post-MIV-150 IVR insertion. Ex vivo SHIV-RT
infection of vaginal, but not ectocervical, tissues collected 14 days post-MIV-150 IVR insertion was significantly inhibited compared to
infection at the baseline (prior to
MIV-150 IVR exposure). No changes in vaginal and ectocervical tissue
infection were observed after placebo IVR exposure. Overall, these data underscore the use of the ex vivo macaque explant challenge models to evaluate tissue and VF PK/PD of candidate
microbicides before in vivo animal efficacy studies. The data support further development of MIV-150-containing IVRs.